FORTREA TO EXPAND CLINICAL TRIALS' DIVERSITY VIA MEDIDATA PARTNERSHIP

KUALA LUMPUR, Nov 21 (Bernama) -- Fortrea, a global contract research organisation (CRO), has partnered with Medidata, to use Medidata AI Intelligent Trials to increase access to diverse patients in clinical trials conducted by Fortrea.

“Medidata’s data and interface capabilities will enhance our ability to seamlessly integrate diverse populations into the clinical trial process. We are thrilled to work with Medidata as part of Fortrea’s go-forward data strategy,” said Fortrea Chief Operating Officer and President of Clinical Services, Mark Morais in a statement.

Meanwhile, Senior Vice President, Medidata AI, Fareed Melhem said Fortrea and Medidata shared a commitment to advancing clinical trial research and this partnership is poised to reshape the landscape of diversity in clinical trials globally.

“Together, our solutions support customers in life sciences to accelerate study timelines and make the benefits of clinical therapies more accessible to a diverse spectrum of individuals,” he said.

Fortrea’s use of Medidata AI builds on an existing collaboration between the two companies, expanding on Fortrea's use of Medidata Rave EDC, an advanced, robust, and secure electronic data capture (EDC) system for clinical trial site, patient and lab data capture and management.

It will leverage features of Medidata AI Intelligent Trials, including study feasibility and diversity data, to help emerging and large biopharmas, as well as medical device and diagnostic companies, achieve enrolment goals that reflect the populations most impacted by each disease or condition under study.

Fortrea’s talented and diverse team of approximately 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

-- BERNAMA